Valeant Urges Fed. Circ. To Revive Antifungal Patent
Law360 (January 22, 2019, 10:15 PM EST) -- The Patent Trial and Appeal Board invalidated a patent covering Valeant Pharmaceuticals’ Jublia by expanding the definition of what the antifungal medication treated, the drugmaker told the Federal Circuit in a bid to revive the patent.
The patent in question treats onychomycosis, fungus of the nail itself, but the PTAB had expanded that definition to also include infections of the skin around the nail, a broadness that cleared it to invalidate the patent, argued patent owner Kaken Pharmaceutical Co. and Valeant, which has rebranded as Bausch Health Cos. Inc.
The patent’s specification, prosecution history and plain meaning all point to onychomycosis meaning...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!